文献速递外周动脉疾病

药物洗脱支架在股腘动脉闭塞随机试验中显示出与人工血管旁路相似的通畅率结果

Drug-Eluting Stent Shows Similar Patency Results as Prosthetic Bypass in Patients with Femoropopliteal Occlusion in a Randomized Trial.
PubMed 文献 · Ann Vasc Surg · 2018-06-07

46例因5-25 cm股浅动脉闭塞导致跛行或静息痛的患者随机分入药物洗脱支架(DES)组与人工血管旁路(BSX)组,随访24个月,最终分析41例。两组在6、12、24个月的二期通畅率及一期、辅助一期通畅率、踝肱指数变化和免截肢生存方面均无统计学显著差异,结果提示DES不劣于人工血管旁路,但研究把握度不足。

要点

  • 46例5-25 cm股浅动脉闭塞患者随机接受药物洗脱支架或人工血管旁路,最终分析41例。
  • 6个月二期通畅率DES组91% vs BSX组83%(P=0.450),12个月分别为74%和80%(P=0.750),24个月分别为56%和71%(P=0.830)。
  • 1、6、12个月一期及辅助一期通畅率两组无统计学显著差异,踝肱指数变化与 major amputation 无显著差异。

核心结论

  • DES与BSX在通畅率及踝肱指数或 major amputation 等临床结局方面无可见差异。
  • 尽管研究把握度不足,结果提示DES不劣于人工血管旁路手术。

研究设计与样本

  • 随机对照试验,46例因5-25 cm股浅动脉闭塞导致跛行或静息痛的患者随机分入DES组与BSX组,随访24个月,最终分析41例。
  • 主要结局指标为总体通畅率,次要结局指标为一期通畅率、辅助一期通畅率、踝肱指数变化和免截肢生存。
  • 试验在ClinicalTrials.org预注册(NCT01450722)。

主要发现

  • 6个月二期通畅率DES组91% vs BSX组83%(P=0.450)。
  • 12个月二期通畅率DES组74% vs BSX组80%(P=0.750)。
  • 24个月二期通畅率DES组56% vs BSX组71%(P=0.830)。
  • 1、6、12个月一期或辅助一期通畅率两组无统计学显著差异。
  • 踝肱指数变化与 major amputation 在两组间无统计学显著差异。

关键数值与推荐

  • 6个月二期通畅率DES组91% vs BSX组83%(P=0.450)。
  • 12个月二期通畅率DES组74% vs BSX组80%(P=0.750)。
  • 24个月二期通畅率DES组56% vs BSX组71%(P=0.830)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文述研究把握度不足(underpowered)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Claudication and critical limb threatening ischemia are significant causes of mortality in the elderly. The gold standard of superficial femoral artery (SFA) revascularization is thus far considered to be the femoropopliteal bypass. The aim of this study was to compare mid-term patency between drug-eluting stents (DESs) and prosthetic bypass grafts (BSX). Studies have reported comparable results for both the methods. METHODS: Forty-six patients with claudication or rest pain due to a 5-25 cm SFA occlusion were randomized between DES and BSX groups. The follow-up period was 24 months, and the primary outcome measure was overall patency. Secondary outcome measures were primary and primary assisted patency, change in ankle-brachial index (ABI), and amputation-free survival. RESULTS: Forty-one patients were eventually analyzed. Six-month secondary patency was 91% (DES) versus 83% (BSX) (P = 0.450). The corresponding numbers at 12 months in the DES and BSX groups were 74% and 80% (P = 0.750), respectively. At 24 months, the respective numbers were 56% and 71% (P = 0.830). There were no statistically significant differences in primary or assisted primary patency at 1, 6, or 12 months. CONCLUSION: There were no demonstrable differences in patency rates or clinical outcomes such as ABI or major amputations between DES and BSX. Although underpowered, the results suggest noninferiority of the DES compared with prosthetic bypass surgery. TRIAL REGISTRATION: The trial was preregistered at ClinicalTrials.org (NCT01450722).

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Björkman P, Auvinen T, Hakovirta H, et al. Drug-Eluting Stent Shows Similar Patency Results as Prosthetic Bypass in Patients with Femoropopliteal Occlusion in a Randomized Trial. Ann Vasc Surg. 2018. PMID: 29886215. doi:10.1016/j.avsg.2018.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。